Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, B-Cell 5Leukemia, Myeloid, Acute 5Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Glioblastoma 4Prostatic Neoplasms 3Multiple Myeloma 3Burkitt Lymphoma 3Triple Negative Breast Neoplasms 2Sarcoma, Synovial 2Ovarian Neoplasms 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Fallopian Tube Neoplasms 2Astrocytoma 2Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Liposarcoma, Myxoid 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphoid 1Leukemia, B-Cell 1Leukemia 1

Interventions

fludarabine phosphate 2Cyclophosphamide 2pevonedistat 1ibrutinib 1Specimen Handling 1Pharmacogenomic Variants 1Leukapheresis 1Etoposide 1Blood Component Removal 1Biopsy 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, B-Cell × Leukapheresis × 1 year × Clear all
NCT05418088 2026-05-29

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡